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Background: The ABSORB Cohort A trial results demonstrated the safety of the ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA) in 30 patients 
with single de novo native coronary artery lesions, with a low long-term MACE rate at 5 years (3.4%) and no scaffold thrombosis. The ABSORB Cohort 
B trial, a continuation of that assessment with a modified ABSORB BVS, enrolled 101 patients at 12 sites in the European and Asia Pacific regions 
between March and November 2009.
Methods: The patients of the ABSORB Cohort B trial were divided into 2 groups, Group B1 (45 patients) having angiographic follow-up performed 
at 180 days and 2 years and Group B2 (56 patients) having angiographic follow-up performed at 1 and 3 years. Key clinical endpoints include 
ischemia driven MACE (ID-MACE) and its components at 30 days, 6, 9 and 18 months, and 1, 2, 3, 4 and 5 years.
Results: In Cohort B, clinical data up to 18 months for the full cohort of 101 patients (Group B1 and B2) are currently available and are summarized 
hereafter. The mean age of patients was 62 years, 72% of patients were male, and 17% of patients were current tobacco users. Patients with diabetes: 
17%, hypertension: 66%, hypercholesterolemia: 85%, family history of CAD: 55%, stable angina: 68 and patients with unstable angina: 15%. Lesion 
location was RCA (33%), LAD (43%), LCX (22%) and Ramus (1%), with an ACC/AHA lesion classification of A for 1% of patients, B1 for 55%, B2 for 40% 
and C for 4%. In these 101 patients, 18 month results showed an ID-MACE rate of 8.0% (3 NQMI and 5 ID-TLR by PCI) and no scaffold thrombosis. 
The 6-month angiographic results from Group B1 and the 1-year angiographic results from Group B2 for ABSORB BVS were comparable to the XIENCE 
V Everolimus Eluting Coronary Stent System in the SPIRIT FIRST First-In-Man trial: (in-scaffold/in-stent late loss: 0.27 mm vs. 0.23mm at 1-year and 
0.18mm vs. 0.10mm at 6-month). The 2-year clinical results for the full cohort of 101 patients from the ABSORB trial will be presented.
Conclusions: Eighteen month clinical outcome of Cohort B was safe; two year clinical follow-up data analysis is pending.
